These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 20172854

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F, Park J, Redemann N, Luippold G, Nar H.
    J Mol Biol; 2014 Feb 20; 426(4):843-52. PubMed ID: 24252255
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
    Cao Y, Yang H, Zhou X, Mao H, Gao T, Hu Z, He L, Pan F, Guo Z.
    Biochem Biophys Res Commun; 2015 Aug 07; 463(4):712-8. PubMed ID: 26056005
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
    Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.
    J Biol Chem; 2013 Mar 22; 288(12):8279-8288. PubMed ID: 23400816
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT, Blanchet M, Seidah NG, Labonté P.
    J Biol Chem; 2015 Sep 18; 290(38):23385-400. PubMed ID: 26195630
    [Abstract] [Full Text] [Related]

  • 13. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
    Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.
    J Biol Chem; 2007 Jul 13; 282(28):20502-12. PubMed ID: 17493938
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.
    Hum Mol Genet; 2012 Mar 15; 21(6):1402-9. PubMed ID: 22156580
    [Abstract] [Full Text] [Related]

  • 16. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
    Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP.
    Hum Mol Genet; 2006 May 01; 15(9):1551-8. PubMed ID: 16571601
    [Abstract] [Full Text] [Related]

  • 17. Molecular basis for LDL receptor recognition by PCSK9.
    Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J.
    Proc Natl Acad Sci U S A; 2008 Feb 12; 105(6):1820-5. PubMed ID: 18250299
    [Abstract] [Full Text] [Related]

  • 18. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K, Essalmani R, Desjardins R, Seidah NG, Day R.
    J Biol Chem; 2016 Nov 18; 291(47):24676-24687. PubMed ID: 27758865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.